PCSK9 Inhibitors.
Cell
| Authors | |
| Keywords | |
| Abstract | Alirocumab and evolocumab are monoclonal antibodies that block proprotein convertase subtilisin/kexin type 9 (PCSK9), a circulating protein that degrades low-density lipoprotein (LDL) receptors. These therapies increase LDL receptors on the cell surface and reduce plasma LDL cholesterol. Both therapies are approved to lower LDL cholesterol, a causative agent for atherosclerotic cardiovascular disease. |
| Year of Publication | 2016
|
| Journal | Cell
|
| Volume | 165
|
| Issue | 5
|
| Pages | 1037
|
| Date Published | 2016 May 19
|
| ISSN | 1097-4172
|
| URL | |
| DOI | 10.1016/j.cell.2016.05.016
|
| PubMed ID | 27203103
|
| Links |